CLSN Celsion Corporation

3.89
+0.06  (2%)
Previous Close 3.83
Open 4.00
Price To book 4.86
Market Cap 32486643
Shares 8,351,322
Volume 1,695,720
Short Ratio 2.90
Av. Daily Volume 3,881,668

SEC filingsSee all SEC filings

  1. 424B3 - Prospectus [Rule 424(b)(3)] 171125357
  2. 8-K - Current report 171120422
  3. 8-K - Current report 171096159
  4. 8-K - Current report 171032449
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171030837

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Final data released December 2015
ThermoDox - Dignity
Recurrent Chest Wall Breast Cancer (RCWBC)
Original Phase 3 trial failed to meet primary endpoint. New Phase 3 trial initiated with enrollment to be completed by mid-2018 with first interim analysis due 1Q 2019.
ThermoDox - OPTIMA
Hepatocellular carcinoma - liver cancer
Phase 1b interim data released at ASCO 2017 - ORR 86%.
GEN-1 OVATION
Ovarian cancer

Latest News

  1. Celsion Provides Summary of Research and Development Day Held on October 12, 2017
  2. This Unknown E-Commerce Stock Could Return 300% in 2017
  3. Celsion Provides Summary of Research and Development Day Held on Thursday, October 12, 2017
  4. Celsion Announces Publication of the HEAT Study Manuscript in the High Impact Journal, Clinical Cancer Research
  5. Celsion to Host Research and Development (R&D) Day on Thursday, October 12, 2017
  6. ETFs with exposure to Celsion Corp. : October 10, 2017
  7. Cancer Space Last Week Update: Pipeline Expansion in Focus
  8. Celsion Corporation Announces Gross Proceeds of $15.6 Million from the Exercise of Existing Common Stock Warrants
  9. Celsion's Immunotherapy Candidate Impresses, Stock Surges
  10. Celsion to Host Research and Development Update October 12, 2017
  11. Updated Outlook and Pipeline Review on Celsion Corporation
  12. Today's Research Reports on Stocks to Watch: Celsion Corporation and Cesca Therapeutics
  13. Celsion Announces Final Clinical and Translational Research Data from its OVATION Study at the AACR Special Conference on Ovarian Cancer
  14. Celsion Provides Update on ThermoDox® in the Phase III OPTIMA Study of Primary Liver Cancer
  15. ETFs with exposure to Celsion Corp. : September 18, 2017
  16. Stocks Near 52-Week Lows: 4 Attractive Picks
  17. ETFs with exposure to Celsion Corp. : August 31, 2017
  18. Celsion Corp. :CLSN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  19. Celsion Announces Presentation of OVATION Study Findings at the Upcoming AACR Special Conference
  20. Edited Transcript of CLSN earnings conference call or presentation 15-Aug-17 3:00pm GMT